A Test For The Early Diagnosis Of Nasal Cancers Head-neck neoplasms can benefit from epigenetics Sinonasal cancers are rare entities comprising 5% of all cancers of the head and neck region, with an annual incidence of about 1 case per 100,000 population worldwide, accounting for 0.5-1% of all malignancies in the Western population. Sinonasal squamous cell carcinoma (SNSCC) and intestinal-type adenocarcinoma (ITAC) account for 80% of all sinonasal cancers. They occur most commonly in adult and elderly men, with a male:female ratio of 2:1 in SNSCC and up to 6:1 in ITAC. The male predominance of sinonasal tumors is probably…
For an overview of Studium Genetics' products, download the information brochures. Read on, go to the page dedicated to the SG-OCRA test for further details. Read on, go to the page dedicated to the SG-Nasal test for further details.
The importance of epigenetics in the care of our smile Incidence and risk factors of oral cancer Cancers in the mouth and throat are more common than you think. Every year, around 750,000 new cases are recorded worldwide, especially in developing countries. And sadly, half of these cases lead to death within five years of diagnosis. The main risk factors include smoking, alcohol consumption and, for some cancers, HPV infection. The most common type of cancer in the mouth is called oral squamous cell carcinoma (OSCC). When it is discovered too late, it is difficult to treat and the chances…
We are pleased to inform our readers that the poster presented by Studium Genetics' researchers and colleagues from the University of Bologna won the first prize for best virtual poster at the AIOCC (Italian Head and Neck Oncology Society) national congress, held in Alba, Italy, last March 13-14th. The poster illustrates the main findings from the article Thirteen-gene DNA methylation analysis of oral brushing samples: a potential surveillance tool for periodic monitoring of treated patients with oral cancer, published in the peer-reviewed journal Head & Neck (v. 46, 4). This study further consolidates the scientific and clinical validation of the…
Studium Genetics, the spin-off Company of Alma Mater Studiorum – University of Bologna, is going to exhibit at Medlab Middle East – Dubai World Trade Center from 5th to 8th February 2024. We are excited to invite you to visit us at booth D53 – Hall Z1 – Italia Pavillon to discover the unique and patented Studium Genetics Collection Kit SG-OCRA™ to access the oral carcinoma risk both in diagnostic and prognostic activities. Prof. Luca Morandi, co-founder and inventor, will be pleased to introduce the Technology. To set a time for a meeting please get in touch writing an e-mail to…
Introduced a new salivary test developed by Studium Genetics, a spin-off of Alma Mater Studiorum - University of Bologna. Milan, Nov. 8, 2023 - A simple salivary test could revolutionize the diagnosis of oral cancers, detecting them in the early stages with outstanding precision. The discovery is the result of research conducted by Studium Genetics, a spin-off of the Alma Mater Studiorum – University of Bologna, which has chosen IRCCS San Raffaele Hospital in Milan (San Donato Group) as a partner to introduce the new methodology into clinical practice and research. The new epigenetic test is based on quantitative analysis…
